Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial-Reference-Cited by-同舟云学术

Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial

Published:2023-12 Issue:12 Volume:11 Page:1051-1063
ISSN:2213-2600
Container-title:The Lancet Respiratory Medicine
language:en
Short-container-title:The Lancet Respiratory Medicine

Author:

Annane Djillali,Pittock Sean J,Kulkarni Hrishikesh S,Pickering Brian W,Khoshnevis Matt R,Siegel Jason L,Powell Charles A,Castro Pedro,Fujii Tomoko,Dunn Derek,Smith Keisha,Mitter Sanjay,Kazani Shamsah,Kulasekararaj Austin

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine

Reference30 articles.

1. Global case fatality rate from COVID-19 has decreased by 96·8% during 2·5 years of the pandemic;Horita;J Med Virol,2023

2. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study;Annane;EClinicalMedicine,2020

3. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients;Holter;Proc Natl Acad Sci USA,2020

4. Complement C5 inhibition in patients with COVID-19—a promising target?;Peffault de Latour;Haematologica,2020

5. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19;Ackermann;N Engl J Med,2020

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Complement system activation: bridging physiology, pathophysiology, and therapy;Intensive Care Medicine;2024-09-10

2. Antibody drugs targeting SARS-CoV-2: Time for a rethink?;Biomedicine & Pharmacotherapy;2024-07

3. Immunotherapy in the context of sepsis-induced immunological dysregulation;Frontiers in Immunology;2024-05-21

4. Plasma protein signatures of adult asthma;Allergy;2024-01-23

5. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial;The Lancet Respiratory Medicine;2023-12